smarp Inhibitors
Smarp inhibitors comprise a collection of chemical entities that target various components of signaling pathways implicated in the regulation of smarp activity. Compounds such as LY294002 and wortmannin function as PI3K inhibitors, curtailing the phosphorylation and subsequent activation of Akt. The result is a suppression of the PI3K/Akt/mTOR signaling cascade, a pathway crucial for the synthesis and function of smarp. This leads to a dampening of smarp activity through diminished synthesis and enhanced degradation. Similarly, triciribine directly inhibits Akt, which further impedes downstream signaling that would otherwise culminate in the activation of smarp. Rapamycin and its analog everolimus target mTOR by forming a complex with FKBP12, inhibiting mTORC1, and consequently, reducing smarp protein levels and functional activity.
Beyond the PI3K/Akt/mTOR pathway, smarp inhibitors like PD98059 and U0126, which are MEK inhibitors, impede the MAPK/ERK pathway, potentially affecting smarp activity through alterations in phosphorylation status and protein stability. The JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 also contribute to the inhibition of smarp activity by interfering with signaling pathways that may regulate smarp's activity or stability. Kinase inhibitors such as sorafenib and dasatinib, which target Raf and Src family kinases, respectively, could lead to reduced smarp activity by preventing necessary phosphorylation events. Gefitinib, an EGFR inhibitor, suppresses smarp activity by inhibiting upstream EGFR signaling, thereby impacting the activation of downstream pathways like PI3K/Akt/mTOR and MAPK/ERK, which are critical for smarp's functional regulation. Each inhibitor, by acting upon specific molecular targets, converges to attenuate the functional activity of smarp through a strategic blockade of its regulatory pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a mTOR inhibitor; it binds to FKBP12 and the complex inhibits mTORC1. mTOR is a downstream effector of PI3K/Akt signaling, which can regulate smarp protein stability and function. Inhibition of mTORC1 by rapamycin can result in reduced smarp activity through decreased protein synthesis and increased autophagic degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of Akt, downstream of PI3K. This leads to decreased activity of the PI3K/Akt/mTOR pathway, which is important for smarp protein synthesis and activity. Inhibition with LY294002 therefore causes a reduction in smarp activity by limiting its production and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which acts by binding covalently to the catalytic site of PI3K, leading to a decrease in Akt phosphorylation and activity. This results in reduced smarp protein synthesis due to the suppression of the PI3K/Akt/mTOR signaling pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an Akt inhibitor that prevents its phosphorylation and activation. By inhibiting Akt, the downstream signaling pathway involving mTOR is affected, leading to decreased smarp protein synthesis and activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR inhibitor similar to rapamycin. It binds to FKBP12, and the resulting complex inhibits mTORC1, which is a key player in the PI3K/Akt/mTOR pathway. This results in decreased smarp protein synthesis and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which interferes with the MAPK/ERK pathway. By inhibiting MEK, the downstream activation of ERK is reduced, which can impact smarp activity if smarp requires ERK-mediated phosphorylation for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents ERK phosphorylation. Inhibition of the MAPK/ERK pathway can decrease smarp activity by affecting its phosphorylation state or protein turnover. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which may inhibit smarp activity if smarp is regulated through JNK-mediated signaling pathways. This compound prevents the activation of JNK, leading to reduced phosphorylation and activity of downstream proteins, potentially including smarp. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If smarp is activated or stabilized through p38 MAPK signaling, then inhibition by SB203580 can result in decreased smarp activity through reduced phosphorylation or altered protein interactions. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor with targets including Raf, which is part of the MAPK/ERK pathway. By inhibiting Raf, sorafenib can reduce smarp activity if smarp is dependent on Raf-mediated phosphorylation or associated signaling events. | ||||||